Standard BioTools Q3 revenue $19.6M, net loss $31.7M; restructuring targets $40M savings

STANDARD BIOTOOLS INC.

2025-Q3 EPS reported -$0.25 revenue$61,536,000

Revenue from continuing ops $19.6M, down 11% YoY; net loss $31.7M vs $21.9M loss in Q3 2024.
Adjusted EBITDA loss $16.5M vs $13.7M loss; restructuring plan cuts ~20% workforce for $40M annual savings.
Cash $217M at Sept 30; expects ~$550M cash at close of Illumina transaction in H1 2026.
FY2025 revenue guidance reaffirmed: combined $165-175M, continuing ops $78-83M.
Gross margin 48.5% (GAAP) and 53.5% (non-GAAP), down from prior year due to volume and mix.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.